1. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-Acting β 2 -Agonist Step-off in Patients With Controlled Asthma: Systematic Review With Meta- analysis Arch Intern Med. 2012;172(18):1365-1375. doi:10.1001/archinternmed.2012.3250 Figure 1. Flow of information through the different stages of the systematic review (for details about the excluded studies, see eAppendix 2). CENTRAL indicates Cochrane Central Register of Controlled Trials. Figure Legend:

2. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-Acting β 2 -Agonist Step-off in Patients With Controlled Asthma: Systematic Review With Meta- analysis Arch Intern Med. 2012;172(18):1365-1375. doi:10.1001/archinternmed.2012.3250 Figure 2. Forest plots of the effects of continuing long-acting β 2 -agonist (LABA) therapy vs stepping off with regard to any use of systemic corticosteroids, asthma control, and quality of life. ACQ indicates Asthma Control Questionnaire; RR, risk ratio. The size of the data marker corresponds to the relative weight assigned in the analysis. *Risk ratio. Mantel-Haenszel method; random effects analysis model. †Data obtained directly from the study sponsor. ‡Inverse variance method; random effects analysis model. §Asthma Quality of Life Questionnaire (AQLQ) (data obtained directly from the study sponsor); higher values indicate better quality of life. Sign of change score was changed to allow same direction of change in both studies. Results favored combination of inhaled corticosteroid plus LABA. ∥ Marks AQLQ; higher values indicate better quality of life. Figure Legend:

3. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-Acting β 2 -Agonist Step-off in Patients With Controlled Asthma: Systematic Review With Meta- analysis Arch Intern Med. 2012;172(18):1365-1375. doi:10.1001/archinternmed.2012.3250 Figure 3. Forest plots of the effects of continuing long-acting β 2 -agonist (LABA) therapy vs stepping off with regard to deterioration of symptoms, night-waking due to asthma, and any serious adverse effect. OR indicates odds ratio; RR, risk ratio. The size of the data marker corresponds to the relative weight assigned in the analysis. *Inverse variance method; random effects analysis model. †Change from baseline. ‡Variability obtained directly from the study sponsor. §Final score. ∥ Control group: breast cancer in situ, traffic accident, musculoskeletal chest pain; experimental group: tension headache; none was deemed related to study medication. ¶Control group: loss of consciousness, car crash, breast cancer, chest pain; experimental group: pulmonary embolism. #Control group: gallstones, severe respiratory tract infection; experimental group: bleeding hemorrhoids, esophageal narrowing, and a cerebral arteriovenous malformation thought to have been congenital. **Control group: cholecystitis; experimental group: herniated lumbar disc, breast cancer. Figure Legend: